A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).
Ana De Jesus-Acosta
No relevant relationships to disclose
Peter J. O'Dwyer
No relevant relationships to disclose
Ramesh K. Ramanathan
No relevant relationships to disclose
Daniel D. Von Hoff
No relevant relationships to disclose
Anirban Maitra
No relevant relationships to disclose
Zeshaan Rasheed
No relevant relationships to disclose
Lei Zheng
No relevant relationships to disclose
N. V. Rajeshkumar
No relevant relationships to disclose
Dung T. Le
No relevant relationships to disclose
Antje Hoering
No relevant relationships to disclose
Vanessa Bolejack
No relevant relationships to disclose
Shinichi Yabuuchi
No relevant relationships to disclose
Daniel A. Laheru
No relevant relationships to disclose